Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is expected to see strong sales revenue and growth potential from their recently approved ophthalmic formulation of bevacizumab, LYTENAVA, for the treatment of wet age-related macular degeneration (wAMD). With a lean sales force model and potential for additional biosimilar products, the company is well-positioned for success in the market. The recent approval and launch in Europe, along with a planned launch in the US, are expected to drive revenue growth, and the company has a strong balance sheet with enough cash to support operations into late-2026. The recent FDA appeal win and resubmission of their BLA, along with partnerships for market access and distribution, further support a positive outlook for the company.

Bears say

Outlook Therapeutics is facing a negative outlook due to several key factors. Lack of commercial momentum in Europe and uncertainty about potential FDA approval for LYTENAVA (ONS-5010) in the US make it difficult to have a positive outlook on the company. Additionally, the company is facing high risks and uncertainties in the drug development industry, including unexpected outcomes from clinical trials and challenges in navigating complex and price-sensitive commercial markets. These factors make it difficult to have confidence in the company's growth prospects and justify a BUY rating.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.